- Record: found
- Abstract: found
- Article: not found
A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.
Pirouz M Daftarian
1 ,
Geoffrey W Stone ,
Leticia Kovalski ,
Manoj Kumar ,
Aram Vosoughi ,
Maitee Urbieta ,
Pat Blackwelder ,
Emre Dikici ,
Paolo Serafini ,
Stephanie Duffort ,
Richard Boodoo ,
Alhelí Rodríguez-Cortés ,
Vance Lemmon ,
Sapna Deo ,
Jordi Alberola ,
Victor L Perez ,
Sylvia Daunert ,
Arba L Ager
Dec 1 2013
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Amphotericin B (AmB), the most effective drug against leishmaniasis, has serious toxicity. As Leishmania species are obligate intracellular parasites of antigen presenting cells (APC), an immunopotentiating APC-specific AmB nanocarrier would be ideally suited to reduce the drug dosage and regimen requirements in leishmaniasis treatment. Here, we report a nanocarrier that results in effective treatment shortening of cutaneous leishmaniasis in a mouse model, while also enhancing L. major specific T-cell immune responses in the infected host.